Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-869 in Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
2007-005245-37Phase 2Completed
- Sponsor
- Abbott Laboratories
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of linifanib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Abbott Laboratories. Primary endpoints: Tumor response by RECIST at low vs high ABT-869 doses and Safety and tolerability of ABT-869. Started Feb 2008; status: completed.
02
Drugs
linifanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2007-005245-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005245-37.